Bio-Rad has sponsored the development of
this site to advance the productivity of the American Biotechnology sector and the fine people who
work in it across the country. We invite readers to contribute content:
posters, tools, research and presentations, articles white papers, multimedia, music
downloads and entertainment, conference announcements, videos. Please contact firstname.lastname@example.org more information.
Download the Protein Blotting Guide
Download the Stem Cell Guide for Life Science Researchers
:: Posted by American Biotechnologist on 08-03-2011
Yesterday, we told you about a study that found that family physicians are ill-prepared when it comes to diagnosing and treating patients based on their genomic data. As a follow up to that story, I’d like to bring your attention to a recent post by W. Gregory Feero, MD, PhD on KevinMD which talks about the overwhelming growth of genomic data and how the pace of discovery is far exceeding the capacity of the health care system’s IT infrastructure.
According to Dr. Feero, medical record keeping in the United States is a far cry away from being able to house the hundreds of petabytes of genomic data that will eventually need to be stored in their systems. Furthermore, upgrading to compatible systems are bound to be prohibitively expensive. He also postulates that the falling cost of genome sequencing might make it cheaper to sequence individual data on an as-needed basis as opposed to storing the data en-masse.
:: Posted by American Biotechnologist on 09-15-2010
A recent article has demonstrated the validity of a new top-down proteomics approach to identifying low-abundance biomarkers in the one per cent of serum/plasma proteins known as the deep proteome. The study used a 4-step approach including sample collection, fractionation with proteominer technology, biomarker discovery with SELDI and biomarker identification using the Lucid system to identify a potential biomarker that might be used to track a patient’s recovery from a myocardial infarction (heart attack).
According to Bio-Rad product manager Dominic Casenas, ‘The workflow in this publication provides scientists with a promising approach for accessing, profiling, and identifying clinically relevant biomarkers.’
:: Posted by American Biotechnologist on 08-27-2010
As discussed in an earlier post, biomarker studies are quickly becoming the hottest research topic around. Many techniques such as 2D, SELDI and Mass Spectrometry are widely deployed in biomarker research. Nonetheless, whichever technique is utilized (a multifaceted approach is generally recommended as each technique contain its own set of advantages) adequate sample preparation is crucially important in obtaining accurate results.
Bio-Rad’s Proteominer technology is a fantastic tool for enriching low abundant proteins which helps identify the proverbial biomarker needle in the protein haystack. In this video, Kate Smith takes you on a tour of Proteominer Enrichment Technology and shows you how it will help you dig deeper into the Proteome.
:: Posted by American Biotechnologist on 06-25-2010
Bio-Rad Laboratories recently announced the launch of 2 multiplex bead array panels for scientist engaged in Diabetes research. The assays are for the detection of 8 mouse and 10 human biomarkers of diabetes and obesity and can be run on Bio-Rad’s Bio-Plex instrument (or other Luminex based platforms).
The Bio-Plex Pro Diabetes Assays only require 12.5 ug of sample and will produce accurate and sensitive results in under 3 hours.
In recognition of the important role that cytokines play in the progression of diabetes, Bio-Rad has ensured that the Bio-Plex Pro Diabetes Assay is fully compatible with its Bio-Plex Pro cytokine, chemokine and growth factor assays. Now diabetes researchers can perform a multi-plex analysis in order to quantify the most important diabetes biomarkers AND cytokine, chemokine and growth factor expression from just 12.5 ug of sample…all in the same tube! This is a huge benefit to any diabetes researcher as it helps eliminate inter-experimental variability that can arise when quantifying analytes from different aliquots of the same sample.
The Bio-Plex Pro Mouse Diabetes Assay includes a multiplex analysis of Ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1 and Resistin. The Bio-Plex Pro Human Diabetes Assay quantifies levels of c-peptide, visfatin, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1 and Resistin in your 12.5 ul sample.
:: Posted by American Biotechnologist on 05-06-2010
Biotechnologists engaged in protein biomarker studies are well aware of some of the challenges they face trying to identify biomarkers in albumin and IgG rich serum and plasma. Protein biomarkers generally tend to be low-abundance proteins which are very difficult to detect among highly complex samples. Furthermore, an ever-increasing amount of biomarker studies are focused on identifying biomarkers in other biological sources such as muscle tissue and cell lines. Traditional approaches to solving this problem include depletion methods for removing high abundant proteins so that the proverbial “needle in the haystack” biomarker is easier to locate. While this approach has its advantages, it suffers from being too specific and may not work well in sample types other than serum and plasma.
Bio-Rad Laboratories Inc. has developed the ProteoMiner protein enrichment technology which uses a library of hexapeptides to bind all proteins in a complex mixture allowing reduction of high-abundance proteins and enrichment of medium and low-abundance proteins.
This Tech Note discusses the use of ProteoMner protein enrichment kits for the enrichment of low- and medium- abundance proteins and the depletion of high-abundance proteins in tissue, cell line and bacterial samples, with detailed experimental parameters in a 2-D gel based proteomics workflow.